Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 13/20 | 0.77 |
| ▸ | PDGFRB | P09619 | 11/20 | 0.77 |
| ▸ | PRKAA1 | Q13131 | 9/20 | 0.77 |
| ▸ | PRKAA2 | P54646 | 8/20 | 0.77 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.77 |
| ▸ | TLK2 | Q86UE8 | 5/20 | 0.77 |
| ▸ | CSF1R | P07333 | 4/20 | 0.77 |
| ▸ | KIT | P10721 | 4/20 | 0.77 |
| ▸ | PLK4 | O00444 | 3/20 | 0.77 |
| ▸ | DCLK1 | O15075 | 3/20 | 0.77 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.77 |
| ▸ | DAPK3 | O43293 | 3/20 | 0.77 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.77 |
| ▸ | RPS6KA5 | O75582 | 3/20 | 0.77 |
| ▸ | RPS6KA4 | O75676 | 3/20 | 0.77 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.77 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.77 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.77 |
| ▸ | INSR | P06213 | 3/20 | 0.77 |
| ▸ | LCK | P06239 | 3/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13711983 | 1.00 | KDR (0.77) | KDRPDGFRBPRKAA1PRKAA2FGFR1 | |
| SCHEMBL4753535 | 0.91 | KDR (0.64) | KDRPDGFRBPRKAA1PRKAA2FGFR1 | |
| SCHEMBL14276345 | 0.90 | KDR (0.69) | KDRPDGFRBPRKAA1PRKAA2FGFR1 | |
| SCHEMBL13755275 | 0.89 | KDR (0.73) | KDRPDGFRBPRKAA1PRKAA2FGFR1 | |
| SCHEMBL4862812 | 0.88 | KDR (0.61) | KDRPDGFRBPRKAA1PRKAA2FGFR1 | |
| SCHEMBL4491029 | 0.88 | PDGFRB (0.72) | KDRPDGFRBPRKAA1PRKAA2FGFR1 | |
| SCHEMBL14276328 | 0.88 | PDGFRB (0.72) | KDRPDGFRBPRKAA1PRKAA2FGFR1 | |
| SCHEMBL24979046 | 0.88 | KDR (0.88) | KDRPDGFRBPRKAA1PRKAA2FGFR1 | |
| SCHEMBL14276351 | 0.88 | PDGFRB (0.71) | KDRPDGFRBPRKAA1PRKAA2FGFR1 | |
| SCHEMBL14276348 | 0.88 | KDR (0.72) | KDRPDGFRBPRKAA1PRKAA2FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582756-B2 | 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors | SUGEN, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20080045709-A1 | 3-(4-AMIDOPYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | SUGEN, INC. | 2008-02-21 | — | — | US | disclosed |
| US-7256189-B2 | 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone der derivatives as protein kinase inhibitors | SUGEN, INC. (US) | 2007-08-14 | — | — | US | disclosed |
| US-7256189-B2 | 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone der derivatives as protein kinase inhibitors | SUGEN, INC. (US) | 2007-08-14 | — | — | US | disclosed |
| US-7179910-B2 | 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-20070027149-A1 | 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone der derivatives as protein kinase inhibitors | SUGEN, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20040152759-A1 | Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders | SUGEN, INC. | 2004-08-05 | — | — | US | disclosed |
| US-20030130280-A1 | Treatment of acute myeloid leukemia with indolinone compounds | SUGEN, INC. | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045709-A1 | 3-(4-AMIDOPYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | MAP4K2, MAP4K3, CDK2 | KDR 762/4885PDGFRB 687/4885PRKAA1 232/4885 |
| US-20040152759-A1 | Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders | MKI67, CCNA1, CCNI | KDR 3687/4885PDGFRB 3475/4885PRKAA1 3094/4885 |
| US-20030130280-A1 | Treatment of acute myeloid leukemia with indolinone compounds | FLT3, FLI1, MCL1 | KDR 71/4885PDGFRB 123/4885PRKAA1 1046/4885 |
| US-20070027149-A1 | 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone der derivatives as protein kinase inhibitors | PDPK1, MAP4K2, MAP4K3 | KDR 1334/4885PDGFRB 1062/4885PRKAA1 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.